Publications and communications of Marilène BINSFELD

Schmitz, L., Pirotte, M., Lebeau, A., Ernst, M., Fillet, M., DEVEY, A., SCHMITT, J., Cobraiville, G., BINSFELD, M., Gofflot, S., Beguin, Y.* , & Vertenoeil, G.*. (2023). Alterations of erythropoiesis in Covid-19 patients: prevalence of positive Coombs tests and iron metabolism. Therapeutic Advances in Hematology, 14, 20406207231199837. doi:10.1177/20406207231199837
* These authors have contributed equally to this work.

BINSFELD, M., GOTHOT, A., & MONFORT, M. (02 February 2018). Detection of RhCE phenotypic variants by serologic routine blood grouping [Poster presentation]. 33rd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
* These authors have contributed equally to this work.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD) [Paper presentation]. Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease [Poster presentation]. 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Jörg, S., Grohme, D., Erzler, M., BINSFELD, M., Haghikia, A., Müller, D., Linker, R., & Kleinewietfeld, M. (04 August 2016). Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cellular and Molecular Life Sciences, 73 (24), 4611-4622. doi:10.1007/s00018-016-2311-1

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Binsfeld, M. (2016). Contribution to the study of immune characteristics in multiple myeloma [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/315244

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
* These authors have contributed equally to this work.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium.

BINSFELD, M., Hannon, M., Humblet-Baron, S., Beguin, Y., Baron, F., & CAERS, J. (30 January 2015). Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models [Poster presentation]. 30th General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Binsfeld, M., HANNON, M., Otjacques, E., Humblet-Baron, S., BAUDOUX, E., BEGUIN, Y., BARON, F., & CAERS, J. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy, 64, 989-998. doi:10.1007/s00262-015-1708-2

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.

Tangen, J.-M., Tierens, A., CAERS, J., BINSFELD, M., Olstad, O. K., Troseid, A.-M. S., Wang, J., Tjonnfjord, G. E., & Hetland, G. (January 2015). Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. BioMed Research International, 2015, 718539. doi:10.1155/2015/718539

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology.

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta - Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.

Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium.

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland.

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.

Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States.

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.

Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2013). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 38.

Otjacques, E., Binsfeld, M., Beguin, Y., Noël, A., Cataldo, D., & CAERS, J. (2013). Aspects biologiques de l'angiogenèse dans le myélome multiple. Oncohématologie, 7 (2), 6-12.

Otjacques, E., Binsfeld, M., Rocks, N., Blacher, S., Vanderkerken, K., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2013). Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. PLoS ONE, 8 (5), 62818. doi:10.1371/journal.pone.0062818

Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2012). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Haematologica, 97 (Supplement 1), 180.

Otjacques, E., Binsfeld, M., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2011). Biological aspects of angiogenesis in multiple myeloma. International Journal of Hematology, 94 (6), 505-18. doi:10.1007/s12185-011-0963-z